BeyondAirInc . (NASDAQ:XAIR) CEO Steven A. Lisi Acquires 10,000 Shares

BeyondAirInc . (NASDAQ:XAIR) CEO Steven A. Lisi bought 10,000 shares of the business’s stock in a transaction on Friday, November 15th. The stock was bought at an average price of $4.09 per share, with a total value of $40,900.00. Following the transaction, the chief executive officer now owns 621,318 shares in the company, valued at $2,541,190.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of XAIR traded up $0.17 during mid-day trading on Monday, hitting $4.20. 41,900 shares of the company’s stock were exchanged, compared to its average volume of 16,794. The firm’s fifty day simple moving average is $4.39. BeyondAirInc . has a twelve month low of $3.11 and a twelve month high of $6.25. The firm has a market capitalization of $42.99 million, a PE ratio of -5.00 and a beta of -0.29.

BeyondAirInc . (NASDAQ:XAIR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). The firm had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.63 million. As a group, analysts predict that BeyondAirInc . will post -1.28 earnings per share for the current fiscal year.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of BeyondAirInc . from a “hold” rating to a “sell” rating in a research report on Saturday, October 19th. ValuEngine downgraded shares of BeyondAirInc . from a “buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Finally, Oppenheimer assumed coverage on shares of BeyondAirInc . in a research report on Tuesday, October 22nd. They issued an “outperform” rating and a $9.00 target price for the company.

BeyondAirInc . Company Profile

Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Featured Article: What is an inverted yield curve?

Insider Buying and Selling by Quarter for BeyondAirInc   . (NASDAQ:XAIR)

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with's FREE daily email newsletter.